A Multi-center, Single-arm Trial Exploring the Safety and Clinical Effectiveness of RBX2660 Administered by Colonoscopy to Adults With Recurrent Clostridioides Difficile Infection
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Ferring Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
have documented evidence of rCDI (≥1 recurrence after a primary CDI episode)
be undergoing antibiotic treatment for the qualifying rCDI episode that was diagnosed by a stool test for the presence of toxigenic C. difficile or C. difficile toxin
be eligible for FMT as judged by the investigator or current treatment guidelines for rCDI in the US
be a candidate for colonoscopy as judged by the investigator
You may not be if
Use or planned use of systemic antibiotics for an indication other than the qualifying rCDI episode.
Current uncontrolled chronic diarrhea not related to CDI.
Receipt of CDI vaccine or treatment with CDI monoclonal antibodies within the past 12 months before screening.
Evidence of active, severe, or fulminant colitis, diagnosis of toxic megacolon or have a current colostomy or ileostomy
